The stock of Dare Bioscience Inc (DARE) has seen a 18.60% increase in the past week, with a 9.69% gain in the past month, and a 61.47% flourish in the past quarter. The volatility ratio for the week is 9.19%, and the volatility levels for the past 30 days are at 10.16% for DARE. The simple moving average for the past 20 days is 9.31% for DARE’s stock, with a 4.24% simple moving average for the past 200 days.
Is It Worth Investing in Dare Bioscience Inc (NASDAQ: DARE) Right Now?
The stock has a 36-month beta value of 1.17. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DARE is 96.84M, and at present, short sellers hold a 0.47% of that float. On March 28, 2024, the average trading volume of DARE was 425.86K shares.
DARE) stock’s latest price update
Dare Bioscience Inc (NASDAQ: DARE)’s stock price has gone rise by 10.17 in comparison to its previous close of 0.50, however, the company has experienced a 18.60% increase in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-21 that SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update.
DARE Trading at 32.66% from the 50-Day Moving Average
After a stumble in the market that brought DARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.09% of loss for the given period.
Volatility was left at 10.16%, however, over the last 30 days, the volatility rate increased by 9.19%, as shares surge +8.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +69.44% upper at present.
During the last 5 trading sessions, DARE rose by +18.60%, which changed the moving average for the period of 200-days by -43.98% in comparison to the 20-day moving average, which settled at $0.5045. In addition, Dare Bioscience Inc saw 77.67% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for DARE
Current profitability levels for the company are sitting at:
- -0.0 for the present operating margin
- 1.0 for the gross margin
The net margin for Dare Bioscience Inc stands at 0.04. The total capital return value is set at 32.59. Equity return is now at value -341.28, with -108.83 for asset returns.
Based on Dare Bioscience Inc (DARE), the company’s capital structure generated -0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -187.96. The debt to equity ratio resting at -0.09. The interest coverage ratio of the stock is 0.1.
Currently, EBITDA for the company is -31.39 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 0.0. The receivables turnover for the company is 8852.33for trailing twelve months and the total asset turnover is 399.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.85.
Conclusion
To sum up, Dare Bioscience Inc (DARE) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
